- Zacks•2 days ago
BioLineRx (BLRX) announced the initiation of a second phase IIa study on BL-8040 in combination with Keytruda for the treatment of pancreatic cancer.
- PR Newswire•4 days agoBioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a second Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The study is part of a research collaboration between MSD and MD Anderson Cancer Center. The open-label, single center, single-arm Phase 2a study aims to evaluate the potential of BL-8040 in combination with KEYTRUDA in pancreatic cancer and focuses on the mechanism-of-action by which both drugs might synergize.
- PR Newswire•17 days ago
BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Philip Serlin, will be presenting at the Biotech Showcase 2017 Conference being held in San Francisco, CA. The BioLineRx presentation is scheduled to start at 2:30 pm PST on Tuesday, January 10, 2017. A live audio webcast of the presentation will be available online at BioLineRx's investor web page.
BLRX : Summary for BioLineRx Ltd. - American Depos - Yahoo Finance
BioLine Rx Ltd (BLRX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||0.75 x 200|
|Ask||0.99 x 2000|
|Day's Range||0.88 - 0.93|
|52 Week Range||0.83 - 1.42|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-3.40|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|